Welcome to our dedicated page for Nutriband Warrant news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband Warrant stock.
Nutriband Inc. is a health and pharmaceutical company based in Oviedo, Florida, primarily focusing on transdermal and topical technologies for product development. Their lead product, AVERSA technology, works to prevent drug abuse and diversion, especially opioids. Most revenue is generated from consumer transdermal and coated products. Nutriband is progressing towards a 505(b)(2) NDA submission to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025.
The recent private placement of $8.4 million will fund the commercial development of AVERSA Fentanyl for NDA filing. Nutriband is working on the commercial scale-up and pivotal clinical study for FDA approval. AVERSA technology aims to revolutionize opioid patches with abuse-deterrent properties, making them safer and more effective.
By utilizing their proprietary AVERSA™ abuse-deterrent technology, Nutriband is dedicated to preventing drug abuse and misuse while ensuring accessibility to those in need. With a focused approach on innovation and safety, Nutriband is positioned to make a significant impact in the pharmaceutical industry.
Nutriband Inc. (NASDAQ:NTRB) reported strong Q3 2024 financial results, with record revenue of $645,796, up 50.94% year-over-year. The company maintains a solid cash position of $5.7 million, with total assets of $12.55 million and stockholders' equity of $11.23 million.
Through its Pocono Pharma subsidiary, Nutriband is expanding its kinesiology tape manufacturing services, with products available in major retailers like Target, Walmart, Walgreens, and CVS. The company continues to progress with AVERSA Fentanyl development, targeting NDA submission in first half of 2025, requiring only a single phase 1 Human Abuse Potential study.
Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
Nutriband Inc. (Nasdaq: NTRB) has announced its participation in the Noble Conference at Florida Atlantic University in Boca Raton on December 3rd-4th, 2024. Company President and Chairman Serguei Melnik will present on December 4th at 1:30 PM in Conference Room 3, focusing on the company's AVERSA technology.
The company specializes in developing transdermal pharmaceutical products, with their flagship product being an abuse-deterrent fentanyl patch incorporating AVERSA™ technology. This innovative technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Presentation details and replay will be available on Channelchek and Youtube after the conference.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Publication for its Hong Kong patent protecting AVERSA™ abuse-deterrent transdermal technology. The patent, assigned Publication Number 40085268 B, will be published on December 20, 2024. AVERSA™ technology is now protected by patents in 46 countries, including major markets. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs like opioids and stimulants. Nutriband is developing AVERSA™ Fentanyl with Kindeva Drug Delivery, potentially becoming the world's first abuse-deterrent opioid patch with projected annual US sales of $80-200 million.
Nutriband (NASDAQ:NTRB) has received full patent issuance from the Chinese National Intellectual Property Administrant (CNIPA) for its 'Abuse and Misuse Deterrent Transdermal System.' The patent (No: ZL 202211158031) supports the company's AVERSA™ technology, developed by 4p Therapeutics, which incorporates taste aversion to prevent abuse of opioid-based transdermal patches. This follows CNIPA's notice of allowance issued in September 2024.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has received approval from the Costa Rica Ministry of Health for its Mosquito Repellent Patch. The product, designed to reduce mosquito bites and associated health risks, will be exclusively distributed through Farmavision S.A. in Costa Rica. Nutriband plans to expand distribution throughout South and Central America.
The global mosquito repellent market is projected to reach USD $9.30 Billion by 2029 with a 5.23% annual growth rate. The patch contains natural ingredients to mask human odors attractive to insects. It's similar to patches approved in African countries like Ghana, Nigeria, and Ivory Coast for reducing malaria and HIV spread.
Nutriband's subsidiary, Pocono Pharmaceutical, will be the exclusive manufacturer of the product.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is hosting an exclusive live investor webinar and Q&A session on October 17, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature Nutriband Founder and CEO Gareth Sheridan and Founder and President Serguei Melnik, who will discuss the company's current operations and upcoming milestones.
Nutriband is addressing the global opioid crisis with its AVERSA™ abuse-deterrent transdermal technology. The company's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million upon FDA approval. Nutriband is pursuing a streamlined 505(b)(2) NDA regulatory pathway, requiring only a single Phase 1 trial with potential for an expedited six-month FDA review.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for its patent application covering the AVERSA™ abuse deterrent transdermal technology. This technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, including opioids and stimulants.
The AVERSA™ technology is now protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA Fentanyl, potentially the world's first abuse-deterrent opioid patch. This product could reach annual US sales of $80 million to $200 million.
The proprietary aversive agent coating employs taste aversion and has shown resistance to removal in preliminary studies. It also features a patented immediate and extended-release profile for additional deterrence.
Nutriband Inc. (NASDAQ:NTRB) has signed a trademark licensing agreement for Bitrex® brand denatonium benzoate, the world's most bitter substance, as an aversive agent in its lead product, AVERSA™ Fentanyl. This abuse-deterrent fentanyl patch incorporates Nutriband's proprietary technology to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The AVERSA™ technology uses a taste aversion coating that is difficult to remove and has a patented immediate and extended-release profile. This additional layer of deterrence prevents easy separation of the drug from the aversive agents. Bitrex® is known for its extremely bitter taste, making products unpalatable and helping prevent accidental ingestion, especially in children.
Nutriband is collaborating with Kindeva Drug Delivery to develop the commercial scale manufacturing process. AVERSA Fentanyl has the potential to be the world's first abuse-deterrent opioid patch, with estimated peak annual US sales of $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has authorized a $1 million share buyback program for its common stock. As of September 16, 2024, the company had 11,106,185 outstanding common shares. Nutriband is primarily focused on developing transdermal pharmaceutical products, with its lead product being an abuse deterrent fentanyl patch incorporating the AVERSA™ abuse deterrence technology. The company maintains its target of submitting an NDA to the FDA in Q1/Q2 2025 for AVERSA Fentanyl. AVERSA™ technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Nutriband Inc. (NASDAQ:NTRB) has released its Q2 2024 financial report, highlighting a strong cash position of $6.75 million and strategic progress towards its NDA filing for AVERSA Fentanyl in 2025. The company is expanding its kinesiology tape contract manufacturing through Pocono Pharma, targeting major retailers. Nutriband aims to submit an NDA for AVERSA Fentanyl to the FDA in Q1/Q2 2025, relying on a single phase 1 Human Abuse Potential study. If approved, AVERSA Fentanyl could be the first abuse-deterrent transdermal patch globally, with estimated peak annual sales of $80-$200 million. The company's total assets are valued at $13.63 million, with stockholders' equity at $12.5 million.
FAQ
What is the current stock price of Nutriband Warrant (NTRBW)?
What is Nutriband Inc.'s primary focus?
What is AVERSA technology?
What is the recent achievement of Nutriband Inc.?
What is Nutriband Inc.'s goal in the pharmaceutical industry?
How is Nutriband Inc. striving for innovation?
